GE Healthcare Life Sciences completes transition into Cytiva
WEBApr 1, 2020 · Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva. The company will retain the same staff, which means that it will have 7,000 employees and possess operations in 40 countries, becoming part of Danaher Corporation Life Sciences platform. CEO and president of Cytiva, Emmanuel Ligner, spoke ...
Sanofi set to acquire Kiadis and K-NK cell platform
WEBNov 2, 2020 · Sanofi and Kiadis have entered into an agreement where Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to fully acquire Kiadis in a deal worth €308m ($358m). While Kiadis' portfolio is focused on cancer therapies, it has also commenced a program evaluating the suitability of K-NK cells against SARS ...
Building a biotech hub: Switzerland focuses on mRNA, CGT and …
WEBSep 8, 2021 · There are 314 biotech companies in Switzerland: broken down into 251 developers and 63 suppliers. Swiss life science exports were valued at CHF 99.1bn ($108bn USD) in 2020 and accounted for 44% of total exports. The sector has grown by a factor of 4.5 since 2000, when life sciences accounted for 17% of …
Cytiva and Pall to spend $1.5bn on manufacturing capacity …
WEBJul 27, 2021 · The investment will include the doubling of capacity in multiple site locations as well as two new sites: one in the UK and one in the US. This is the largest investment in capacity to date for Pall and Cytiva, following five acquisitions made by the companies this year and an additional US$500m in previously-announced investments.
SGS owned CDMO to develop and manufacture IBD focused live ...
WEBApr 14, 2022 · Xbiome acquires live biotherapeutic product program targeting ulcerative colitis. US and South Korean microbiome CDMO partnership to build US facility. Kaleido Biosciences is winding up operations as bluebird bio and other biotech firms announce layoffs. Quay Pharma, a contract development and …
Pharma and biopharma outsourcing strategies need to use an …
WEBOct 26, 2022 · But a new CPhI report on 'The Future of Outsourcing' advises against this approach. “Traditionally, outsourcing strategies were designed to help secure next stage funding, but many biotechs and small pharma companies are now entering development with more robust cash flows and the ability to plan further downstream," "This opens the …
Ardena buys Spain’s Idifarma in move to capitalize on emerging …
WEBSep 6, 2021 · Established in 2001, Idifarma now has 120 employees. Harry Christiaens, CEO of Ardena, said the deal expands the CDMO’s pharmaceutical technology footprint, positioning it to capitalize on the emerging biotech segment and broader pharmaceutical market. “ In partnership with GHO Capital, we will continue to …
Touchlight set to break ground on world’s highest-capacity DNA ...
WEBOct 18, 2021 · The facility will house 11 new DNA production suites, bringing the total on site to 15 and more than tripling Touchlight’s London-based DNA manufacturing capacity. Once operational in 2022, the biotech said the site will have the capacity to manufacture up to 1kg of GMP DNA per month. That will be more than any other single site worldwide, it ...
Swiss biotech R&D investments reach record high
WEBMay 9, 2022 · News and analysis on the clinical development and manufacture of large molecule drugs. Capital investments in Swiss biotech companies reached CHF 3.33bn ($3.53bn) in 2021; while R&D investments increased to a record-high CHF 2.56bn ($2.71bn). While the Swiss biotech sector has been involved in fighting COVID-19 (Humabs BioMed/Vir Biotechnology ...
Sanofi to acquire Translate Bio to develop mRNA tech across …
WEBAug 3, 2021 · Sanofi will acquire clinical-stage mRNA therapeutics company Translate Bio for $3.2bn. Sanofi has partnered with Translate Bio since 2018 on mRNA vaccines; most recently with a COVID-19 vaccine candidate. Coming on the back of its announcement to build an mRNA Center of Excellence, Sanofi says the acquisition will help accelerate development of ...
Skip to content